Last Updated : April 24, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Translarna | ataluren | Cancelled | ||||
| Atriance | Nelarabine | Cancelled | ||||
| TBD | Trastuzumab | Cancelled | ||||
| Truxima | Rituximab | Cancelled | ||||
| TBC | tirzepatide | Diabetes mellitus, type 2 | Cancelled | |||
| Onivyde | Nanoliposomal Irinotecan | Cancelled | ||||
| Pradaxa | Dabigatran etexilate | Atrial fibrillation prevention of stroke and systemic embolism | Cancelled | |||
| Brilinta | Ticagrelor | Acute Coronary Syndromes | Cancelled | |||
| Twynsta | Telmisartan / Amlodipine | Hypertension | Cancelled | |||
| BuTrans | Buprenorphine transdermal patch | Pain, persistent (moderate intensity) | Cancelled |
Last Updated : April 24, 2024